According to the findings of a study, increased 18F-THK5351 uptake may be a valuable predictor of poor prognosis among β-amyloid negative amnestic mild cognitive impairment people, which may be linked with increased neuroinflammation in the brain. Researchers assessed the association between 18F-THK5351 positron emission tomography positivity and cognitive dysfunction in people with mild cognitive decline.

Overall, 25 participants who underwent at least 2 follow-up neuropsychological assessments, including clinical dementia rating-sum of boxes (CDR-SOB) were segregated into 18F-THK5351-positive (n=10) and 18F-THK5351-negative (n=15) arms. For estimating the effects of 18F-THK5351 positron emission tomography positivity on cognitive prognosis among β-amyloid negative-cognitive impairment people, a linear mixed-effects model was utilized. Among 25 β-amyloid negative- amnestic mild cognitive impairment people, 10 (40.0%) were found to be 18F-THK5351 positive.

Subjects in the 18F-THK5351-positive group were older when compared to the 18F-THK5351-negative group (77.4±2.2 years vs. 70.0±5.5 years). Regarding the percentage of apolipoprotein E ε4 carriers,  no profound inter-group difference was witnessed. In comparison with the 18F-THK5351-negative group, the 18F-THK5351-positive group exhibited a faster deterioration of CDR-SOB scores.